Statins are the most widely used lipid-lowering drugs. By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase they block the rate-limiting step of cholesterol synthesis, resulting in up-regulation of low density lipoprotein (LDL) receptors on liver cell membranes, reduced plasma LDL, and reduced atherosclerosis. In addition to their lipid lowering effects, statins reduce inflammation by effects on many other cells. These include lymphocyte-suppressing effects in patients with elevated cholesterol levels [1] . The anti-inflammatory effects of statins are secondary to HMGCoA inhibition and result from diminished post-translational protein prenylation of small G proteins such as Ras and Rho, which are important signaling molecules that regulate antigen presenting cells (APCs) and lymphocytes [2] . RhoH has recently been shown to serve as an adaptor molecule that regulates the subcellular localization of the proximal T cell signaling molecules, lymphocyte-specific protein tyrosine kinase (Lck) and Zeta-chain-associated protein kinase 70 (Zap-70) [3] (Fig. 1) .
The antigens that activate most T cell receptors are peptides presented by MHC on APCs. In a minor subset of lymphocytes known as iNKTcells, certain lipid antigens are presented by the MHC-like molecule, CD1d. The TCRs of iNKT cells are not variable, as is the case for most TCRs, but rather are invariant. Some of the antigens that activate iNKT cells are derived from the membrane lipids of microbes and rapidly activate iNKT cells to provide host defense against infection [4] . In addition, antigen presenting cells are stimulated to synthesize endogenous glycolipid antigens in response to the activation of Toll like receptors (TLRs) on antigen presenting cells [5] . Although iNKT cells play a protective role in host defense against microbial infections, in diseases such as atherosclerosis, sickle cell anemia and asthma, iNKT cell activation can be deleterious to the host [6, 7] .
In this issue, Nakou et al. [8] demonstrate that hyperlipidemic individuals have significantly lower numbers of circulating iNKT cells than controls. During 6 months of therapy with 40 mg/day simvastatin, the number of iNKT cells in hyperlipidemic patients increased significantly to near control levels. The increase in circulating iNKT cells in the patients receiving simvastatin appeared not to be due to lipid lowering because there was no relationship between plasma lipids or triglycerides and numbers of iNKT cells in blood. Moreover, the response to another lipid lowering drug, ezetimibe (10 mg/day) was similar to simvastatin in changing plasma lipid profiles of hyperlipidemic patients, but ezetimibe failed to increase numbers of circulating iNKT cells. Unlike statins, which inhibit HMG-CoA, ezetimibe inhibits the absorption of cholesterol in the small intestine. Nakou et al. conclude that the effect of simvastatin to increase circulating iNKT cells in hyperlipidemic patients is not due to the lipid-lowering effects of the statin.
It remains to be determined why simvastatin increases the number of circulating iNKT cells in hyperlipidemic patients and if the increase is of benefit to the patient. Since iNKT cells have been shown to accelerate atherosclerosis progression, the increase in circulating iNKT cells could be viewed as detrimental. However, if simvastatin inhibits the activation of iNKT cells it is likely to reduce the ability of these cells to exacerbate plaque inflammation. Nakou et al. used flow cytometry to measure the expression on iNKT cells of the activation marker, HLA-DR. They found that the percentage of HLA-DR positive iNKT cells in hyperlipidemic patients is significantly higher than in controls, consistent with greater iNKT activation. Treatment with simvastatin for 6 months lowered the fraction of circulating iNKT cells expressing HLA-DR, but this effect was not statistically significant. Nevertheless, it still remains possible that simvastatin treatment inhibits iNKT cell activation to produce an anti-inflammatory and beneficial effect in patients with atherosclerosis. Nakou et al. point out that by inhibiting iNKT cell activation, statins may increase the number of iNKT cells by reducing activation induced cell death (AICD). It is also possible that statins alter cytokine production by activated iNKT cells. One of the interesting characteristics of iNKT cells is that they can produce both pro-inflammatory Th-1 cytokines such as IFNγ, and anti-inflammatory Th-2 cytokines such as IL-4. In addition, iNKT cells can inhibit the development of strongly pro-inflammatory Th-17 cells [9] that are thought to play a role in atherosclerosis progression [10, 11] . An increase in Th-2 cytokines by iNKT cells could also contribute to another anti-inflammatory and plaque-stabilizing effect of statins, i.e. increased production of regulatory T cells [12] . It is significant also that most iNKT cells in the vascular space are not found in the blood stream but rather are loosely adhered to the walls of blood vessels [13] . It is likely that adhered iNKT cells are more activated than circulating cells. Treatment with simvastatin may alter the fraction of iNKT cells that are found in the circulation, so the number of iNKT cells found in blood is not necessarily indicative of the number of iNKT cells found in inflamed sites such as atherosclerotic plaques.
In summary, Nakou et al. have demonstrated a novel effect of statins to increase the number of circulating iNKT cells in hyperlipidemic patients. Since iNKT cells can have either a pro-inflammatory or anti-inflammatory character, it remains to be determined if this effect increases or inhibits inflammation in atherosclerotic plaques. However, based on the known effects of statins to inhibit the activation of APCs and lymphocytes, it is likely that the effects of statins on iNKT cells are beneficial for inhibiting the progression of atherosclerosis. 
